The test uses a peptide fluorescent probe to identify the interaction between a peptide (peptide ß-amyloid 1-42) and the red blood cell membranes by using one drop of blood.
The test enables early detection and monitoring of Alzheimer’s if it targets the amyloid trajectory.
The proof of concept for this test was obtained following a first clinical trial which was concluded at the end of 2010.
IHD president Xavier Regnaut said the results of study with IHD-Amy validates its potential as a diagnostic aid tool for doctors.
